Enanta Pharmaceuticals | ENTA - Fremdkapital

Aktienkurs
12.69
Täglich Wechseln
0.18 1.44%
Monatlich
-13.97%
Jährlich
104.68%
Q1 Prognose
12.13




Fremdkapital Veränderung Datum
AbbVie USD 62.97B 12M 2025-09
Amgen USD 50B 2.43B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Biogen USD 6.29B 1.4M 2025-09
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 22.14B 5M 2025-09
GlaxoSmithKline GBP 14.71B 186M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Immunic USD 0 0 2024-06
Incyte USD 30.2M 5.17M 2025-12
Insmed USD 540.96M 1.24M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
J&J USD 39.44B 30M 2025-12
Karyopharm Therapeutics USD -0.93 0.67 2024-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 39.97B 6B 2025-09
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 29.59B 5.35B 2025-12
Novavax USD 246.3M 200K 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03